Clinical trials: Bone Volume, open to volunteers
Myelofibrosis, Moderate Thrombocytopenia
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction…
- Conditions
- Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
- Trial name
- SENTRY-2 (NCT05980806)
- Testing
- Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib
- Where
- 70 sites in United States, Belgium and 17 more
- Volunteers
- 58 people
- Sponsor
- Karyopharm Therapeutics Inc